Mushroom Coffee Market & Brands
$3.23B global market in 2025
The mushroom coffee market reached $3.23 billion in 2025 and is projected to grow to $5.56 billion by 2035. The category traces its origins not to a Silicon Valley startup but to wartime Finland, where coffee rationing in the 1940s led to chaga mushroom as a substitute.
Market research data, 2025; Yang et al., Frontiers in Cellular and Infection Microbiology, 2025
5.58% CAGR
projected growth rate through 2035
29%
North America's share of the global mushroom coffee market
2009
year the lion's mane RCT provided category-defining scientific credibility
Market research data, 2025; Yang et al., Frontiers in Cellular and Infection Microbiology, 2025
View as image ↗Mushroom coffee did not start as a wellness trend. It started as a wartime necessity.
During World War II, Finland faced severe coffee rationing as supply lines from colonial plantations collapsed. Finnish households began brewing chaga, the birch-parasitic mushroom that grows wild across Nordic forests, as a coffee substitute. The beverage had the dark color, the slight bitterness, and enough sensory resemblance to coffee to fill the ritual gap when the real thing was unavailable. Finnish families who grew up drinking chaga tea never entirely stopped, and the tradition persisted quietly in Nordic wellness culture for decades after the war ended.
That historical memory is one of the reasons Tero Isokauppila, who grew up on a Finnish family farm, saw a market opportunity when he moved to the United States. His view was that mushrooms in coffee were not a novelty but a return to something older than the instant coffee category. He founded Four Sigmatic in 2015, and within five years he had single-handedly created a new food and beverage category. By 2025, that category was worth $3.23 billion globally.
This is the story of how that happened, and what the underlying science actually supports. For the current market breakdown and major players, see The Mushroom Coffee Boom: Market Size and Major Players. For the broader functional mushroom market context, see The Functional Mushroom Market: Size, Growth, and Projections.
Key Takeaways
- Mushroom coffee traces its origins to wartime Finland, where chaga was used as a coffee substitute during WWII rationing, creating a cultural precedent that Tero Isokauppila drew on when founding Four Sigmatic in 2015
- The scientific credibility that made the category investable came largely from the Mori 2009 lion's mane RCT: 30 adults with mild cognitive impairment showed significant improvement on 3g/day, giving brands the cognitive benefit narrative they needed
- The chemistry basis: hericenones (fruiting body compounds) and erinacines (mycelium compounds) are the lion's mane bioactives behind cognitive claims; which one a product contains depends on whether it uses fruiting body or mycelium extract
- The DTC playbook that built the category: Four Sigmatic pioneered "upgrade the existing habit" rather than replacement; RYZE added a Harvard-graduate credibility narrative; MUD\WTR repositioned around anti-caffeine-dependence
- The market reached $3.23 billion in 2025, with North America holding 29% market share and a projected 5.58% CAGR through 2035
- The honest tension: clinical trials used 1.8-3g of lion's mane per day; most mushroom coffee products deliver significantly less per serving
The Origin Story: Wartime Finland and Chaga Tea
The story that Tero Isokauppila tells about Four Sigmatic begins on his family's farm, where chaga was not a wellness supplement but a kitchen staple. His grandmother brewed chaga the way other Finns had since the 1940s: as a practical substitute for coffee when coffee was unavailable.
Chaga (Inonotus obliquus) grows as a dark, irregular mass on birch trees across northern forests. It is not the most bioactively complex mushroom, but it is visually striking, unusually dark when powdered, and has enough compounds (including betulinic acid derivatives absorbed from birch bark and a range of antioxidants) to produce a beverage that feels substantial. Finnish households who adopted it during rationing found it serviceable enough to keep using it long after coffee returned to store shelves.
Mushrooms have also been used in traditional Chinese medicine for centuries. Cordyceps has been prescribed for respiratory health and fatigue since at least the 15th century in TCM texts. Reishi (Ganoderma lucidum) has been called the "mushroom of immortality" in Chinese herbalism for over 2,000 years. These traditions gave medicinal mushroom advocates a historical lineage to cite, and they positioned the modern functional mushroom market as rediscovery rather than invention.
Neither of these traditions, however, involves mushroom coffee specifically. The combination of coffee with medicinal mushrooms was a modern invention, and its success depended on something neither the Finnish chaga tradition nor TCM provided: scientific data.
The Study That Made Investors Believe: Mori 2009
The single most important event in the creation of the mushroom coffee category was not a product launch or a marketing campaign. It was a clinical trial.
Mori and colleagues published a double-blind, placebo-controlled study in Phytotherapy Research in 2009 testing Hericium erinaceus (lion's mane) in adults with mild cognitive impairment.[1] Thirty patients participated, receiving either 3 grams per day of lion's mane powder or placebo for 16 weeks. By week 8, the lion's mane group had significantly higher cognitive function scores on two validated assessments (the MMSE and the Revised Hasegawa Dementia Scale) compared to the placebo group. By week 16, the gap had widened.
One finding buried in the Mori 2009 paper was important: after stopping supplementation, the cognitive scores of the lion's mane group declined back toward baseline over the following four weeks. The benefit required continued use.
This study gave the functional mushroom category what it lacked: a peer-reviewed, double-blind, placebo-controlled human clinical trial showing measurable cognitive benefit from a specific mushroom at a specific dose. It was small (n=30), it was in patients with existing cognitive impairment rather than healthy adults, and the reversal after stopping was a significant limitation. But it was real data, published in a respectable journal, and it created the "brain performance" narrative that eventually became the central claim of the mushroom coffee category.[1]
For the full context on the lion's mane cognitive evidence, see what Isokauppila and other founders drew on when positioning their products; the Mori 2009 study is the cornerstone.
The Chemistry Behind the Claims: What Hericenones and Erinacines Are
The cognitive claims in mushroom coffee marketing rest on two compound classes. Friedman's 2015 chemistry review in the Journal of Agricultural and Food Chemistry established the taxonomy that the supplement industry built on.[2]
Hericenones (C through H) are compounds from the lion's mane fruiting body. They stimulate nerve growth factor (NGF) in peripheral tissues and, via pan-neurotrophic ERK1/2 signaling, activate multiple neurotrophic pathways in brain cells. They are the active compounds in products that use lion's mane fruiting body extract.
Erinacines (A through K) are compounds from the lion's mane mycelium. They cross the blood-brain barrier by passive diffusion (due to their small molecular weight and lipophilic structure) and directly stimulate NGF and BDNF production inside brain tissue. They are the active compounds in products that use erinacine-enriched mycelium.
The Mori 2009 study used lion's mane fruiting body powder, meaning hericenones were the relevant compounds in the study that created the cognitive credibility narrative. Products that use mycelium instead of fruiting body will contain erinacines but not hericenones. Both have CNS-relevant activity, but through different mechanisms and with different evidence bases.[2]
This distinction matters for evaluating brands, a topic covered in depth in Mushroom Coffee Brands Compared: MUD\WTR, Ryze, Four Sigmatic, and More. The short version: a product's source material determines which compounds are present and which mechanisms are active.
How Four Sigmatic Built the Category (2015-2020)
Isokauppila's core insight was not to replace coffee but to upgrade it. Instead of asking consumers to give up their morning ritual, he added mushroom extracts to coffee, positioning the combination as coffee with added cognitive support. The ritual stayed; the functional claim was new.
This "upgrade the existing habit" strategy was the category's founding logic, and it proved prescient. Energy drink categories typically require consumers to adopt a new consumption habit. Mushroom coffee required them to change nothing except which coffee product they bought. The barrier was lower than competitors had anticipated.
Four Sigmatic's early products used lion's mane and chaga in combination with high-quality Arabica coffee. The lion's mane provided the cognitive narrative (anchored to Mori 2009); the chaga provided the origin story (Finnish tradition, antioxidant claims). Both were positioned as "functional" rather than pharmaceutical, which kept the products out of drug classification and within the supplement market's much lighter regulatory framework.
The company grew rapidly in the natural grocery channel (Whole Foods was an early retail partner) and online. By 2019, Four Sigmatic had raised venture capital and was being covered in mainstream media as a legitimate wellness brand, not just a quirky niche product. The word "billion-dollar category" was first used by industry analysts around this period, though actual revenues were still tens of millions.
The DTC Playbook: RYZE, MUD\WTR, and What Followed
Four Sigmatic's success demonstrated that the mushroom coffee market existed. What followed was a wave of direct-to-consumer brands applying different positioning strategies to the same consumer appetite.
RYZE launched around 2020, founded by two Harvard graduates who positioned the brand around a blend of six mushroom species (lion's mane, cordyceps, reishi, shiitake, turkey tail, king trumpet) combined with MCT oil and organic coffee. The Harvard founder narrative gave the brand credibility with an audience that responds to credentials. RYZE grew rapidly through social media advertising, particularly on platforms where fitness and biohacking communities were active. The brand used a subscription model that locked in recurring revenue and made customer acquisition economics more favorable.
MUD\WTR took a different approach: explicitly positioning against coffee dependence rather than alongside it. The product contains only 35mg of caffeine (compared to 80-100mg in a typical cup of coffee) and is cacao and chai-spiced rather than coffee-based. Its founder, Shane Heath, built the brand around the narrative of breaking caffeine addiction and replacing it with something that provides focus without jitters. MUD\WTR appealed to the subset of coffee drinkers who wanted to reduce rather than maintain their caffeine consumption, a meaningful but distinct consumer segment.
By 2022, the mushroom coffee category had expanded into mainstream retail beyond Whole Foods and natural grocery, reaching Target, Walmart, and Amazon as primary distribution points. Category velocity in Amazon's supplement subcategories drove further investment in the space, and smaller brands proliferated.
The commercial trajectory of these functional mushroom products is documented in the Gopal 2022 review in Nutrients, which traced how Asian medicinal mushroom species transitioned from traditional medicine to global functional beverage products, with convenience and clinical credibility as the primary market drivers.[4]
The Market Today: $3.23 Billion and Growing
By 2025, the mushroom coffee market had become a measurable and stable category segment within the broader functional beverage industry. Market research data places the category at $3.23 billion globally in 2025, with a projected compound annual growth rate of 5.58% through 2035, reaching an estimated $5.56 billion.
North America holds approximately 29% of the global mushroom coffee market. The Asia-Pacific region is growing fastest, driven by increasing urbanization and a wellness consumer trend that mirrors the US trajectory approximately five to eight years delayed. Lion's mane-based products dominate the species segment; powder format accounts for approximately 64% of total product sales.
The Niego 2021 review of macrofungi nutraceuticals confirmed that functional beverage applications represented one of the highest-growth commercial opportunities for medicinal mushrooms, driven by consumer preference for health products in convenient, familiar delivery formats.[3]
The Yang 2025 comprehensive review in Frontiers in Cellular and Infection Microbiology, covering the full landscape of medicinal mushrooms in health-boosting beverages, identified mushroom coffee as one of three dominant beverage formats alongside mushroom tea and mushroom protein drinks, noting that the category's growth had moved significantly faster than the broader supplement market across the same period.[5]
The Honest Question: What Does the Science Support?
The category was built on claims about cognitive performance, focus, immune support, and stress reduction. Some of these claims have better evidence than others.
The Mori 2009 trial that gave the category its scientific credibility used 3 grams of lion's mane per day for 16 weeks in patients with mild cognitive impairment.[1] Most mushroom coffee products deliver somewhere between 150 and 500 milligrams of each mushroom species per serving. Six times less at the conservative end.
The clinical evidence base for functional mushrooms is genuinely promising but consistently uses doses that consumer products do not typically reach. The Yang 2025 review acknowledged this as a key limitation in translating functional mushroom research to commercial beverage products, noting that extraction quality and dose standardization remain inconsistent across the commercial market.[5]
This tension between clinical doses and commercial doses does not mean mushroom coffee is inert. Bioactive compounds from mushrooms do survive coffee brewing when fruiting body extracts are used, as confirmed in laboratory analysis of infused coffee products. And some benefits may operate at lower doses than the clinical trials used. But the marketing has consistently outrun the dose-matched evidence.
The category's next competitive phase will likely be won by brands that invest in extraction quality, third-party testing, and dose transparency, the elements that distinguish products whose claims are defensible from those whose are not.
For the deeper dive on what the clinical evidence says about specific mushroom species, see Is the Mushroom Coffee Trend Sustainable or a Fad?. For the quality analysis of which brands deliver on their claims, see Do Mushroom Coffee Products Have Enough Mushroom to Matter? and Fruiting Body vs. Mycelium on Grain: The Debate That Defines Mushroom Supplement Quality.
The Bottom Line
Mushroom coffee emerged from a wartime necessity in Finland, was commercialized by Tero Isokauppila through Four Sigmatic in 2015, and grew into a $3.23 billion global category by 2025 through a combination of scientific credibility (the 2009 Mori lion's mane RCT), DTC brand building, and consumers' appetite for functional alternatives to conventional coffee. The category's growth rests on cognitive benefit claims primarily anchored to lion's mane research, with hericenones from fruiting body and erinacines from mycelium as the two active compound classes. The honest tension at the category's core: clinical trials used 1.8-3g of mushroom per day, while most commercial products deliver significantly less. The brands that survive market consolidation will likely be those that compete on dose transparency and extraction quality rather than on narrative alone.
Frequently Asked Questions
Sources & References
- 1RTHM-00165·Mori, Koichiro et al. (2009). “Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial..” Phytotherapy research : PTR.Study breakdown →PubMed →↩
- 2RTHM-00371·Friedman, Mendel (2015). “Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion's Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
- 3RTHM-01414·Niego, Allen Grace et al. (2021). “Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value..” Journal of fungi (Basel.Study breakdown →PubMed →↩
- 4RTHM-01525·Gopal, Judy et al. (2022). “Scrutinizing the Nutritional Aspects of Asian Mushrooms, Its Commercialization and Scope for Value-Added Products..” Nutrients.Study breakdown →PubMed →↩
- 5RTHM-02215·Yang, Jing-Ya et al. (2025). “Innovative applications of medicinal mushrooms in functional foods and nutraceuticals: a focus on health-boosting beverages..” Frontiers in cellular and infection microbiology.Study breakdown →PubMed →↩